PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a Master Services Agreement dated effective October 1, 2018 (the "Agreement") with World Wide Holdings LLC, DBA Invictus Resources ("Invictus"), whereby Invictus will provide investor awareness services (the "Services") to the Company involving the selection and coordination of investor awareness providers and services.
Under the terms of the Agreement, Invictus will advise and assist PreveCeutical in developing its business plans and strategies for presentation to existing and potential investors, as well as raising market awareness of the Company and providing introductions to its contacts in the financial community, including brokers and micro-cap funds.
In consideration for the provision of the Services by Invictus, the Company will issue 4,000,000 stock options to Invictus, each of which options will be exercisable to acquire one common share in the capital of the Company for a period of one year at a price equal to the greater of the closing price of Company's common shares on the Canadian Securities Exchange on September 28, 2018 and on October 1, 2018, which options will vest over 10 months, as to 10% each month. Invictus will also receive a cash payment of USD $80,000 for the initial term of the Agreement (the "Initial Term").
The Initial Term is one month and, subject to the mutual agreement of the parties, shall thereafter be automatically renewed for up to three successive one-month terms. Upon each subsequent renewal, Invictus shall receive a cash payment of USD $80,000.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on PreveCeutical's website.
For further information, please contact:
PREVECEUTICAL MEDICAL INC.
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the Services to be provided by Invictus pursuant to the Agreement and the anticipated benefits of the Services, the Company's anticipated business plans and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, performance, industry trends and growth opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and the Agreement, complete its research programs as planned, obtain the financing required to carry out its planned future activities and the ability and success of Invictus in carrying out its engagement with the Company. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare, cannabis, biotechnology or pharmaceutical industries, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.